• Accelerating the Growth of Natural Botanical Medicine to Solve the Healthcare Crisis


  • The Problem

    Mainstream Drugs Do Not Help Patients Recover From Disease


    Although the US spends twice as much on healthcare than other high-income nations, the US remains the sickest first world country on earth. Compared to other developed countries, the US has the shortest life expectancy and highest infant mortality rate. Plagued with chronic degenerative diseases, the vast majority of American patients are treated with expensive drugs that only mask symptoms and are filled with side effects. These same drugs have become the standard of care in many countries all over the world. When patients do not recover from disease, most end up in hospitals sooner or later. Endless patient hospitalizations are bankrupting our healthcare systems.


    Many companies produce natural botanical therapies that are more effective, safer and cheaper than mainstream drugs. Botanical therapies treat the root cause of disease and the best botanicals can reverse acute and chronic diseases with sustained results and no side effects. In 2004 the FDA developed guidelines for botanical therapies to become approved botanical drugs. Just like conventional drugs, botanical drugs are prescribed to patients to treat disease and have insurance coverage. Unfortunately patients never find out about these treatments because botanical companies are neglected and do not have equal access to resources for clinical trials.

  • Our Solution

    Enable Botanical Medicine to Flourish Globally

    In 2016 the FDA relaxed botanical drug approval guidelines to catch up with global standards, creating a huge opportunity for the worldwide expansion of botanical medicine. The global botanical medicine industry is an open and untapped $300 billion market. PhytaZenica ("fai-tuh-zeh-ni-kuh") is a healthcare tech company that provides digital products and services to accelerate the development and approval of botanical medicine. Our digital platform provides resources to help facilitate botanical clinical trials, approval and commercialization, as well as provide clinical trial design for botanical therapies.


    Led by a team of world-class healthcare and technology experts, PhytaZenica is driving the expansion of botanical medicine to transform global healthcare. PhytaZenica is:

    • a best-in-class marketplace
    • one-stop shop for the botanical industry

  • The Meaning of "PhytaZenica"


    The word “phyta” ("fai-tuh") is a suffix used in scientific names for plants. We are focused on driving the worldwide expansion of botanical medicine made from all-natural botanical ingredients.


    Originating from the Slovenian, Serbian and Croatian languages, the word “zenica” means the “pupil” of the eye. In some cultures, the eyes symbolize a message of prophesy, literally seeing “a vision of the future”. We are always keeping an eye on the future.


    PhytaZenica represents the future of botanical medicine. Together, we seek to:

    • Redefine disease therapy: botanical therapies that reverse acute and chronic diseases with sustained results and no side effects or contraindications
    • Redefine patient convenience: short-term treatments with long-term results; patients deserve to recover from disease without taking medications forever
    • Redefine mainstream healthcare: our mission is to transform global healthcare by launching botanical therapies that are superior in efficacy, safety, and cost compared to the current standard of care

    PhytaZenica makes socially responsible medicine to solve the healthcare crisis by providing better treatments for patients worldwide. Join us and spread the word. The healthcare revolution is here.



  • Our Team

    Jennifer Wong

    Founder & Chief Executive Officer


    Jennifer created the original vision for PhytaZenica and is leading the strategic and overall execution of our venture. She has over 10 years of experience in business strategy, market research, competitive intelligence, marketing and sales for the healthcare and biopharmaceutical drug industries. Jennifer has worked closely with top global biotech and pharmaceutical companies, as well as botanical companies in the US. Jennifer holds a bachelor’s degree in Integrative Biology from UC Berkeley.


    Sam Nanayakkara

    Technology & Strategy


    Sam is a serial entrepreneur with 30 years of experience in digital technology leadership.  He specializes in Web2 + Web3, analytics, marketing, operations and supply chain for the technology, finance, healthcare, aerospace, manufacturing, and insurance industries. Before the age of 30, Sam successfully started 6 companies in the finance and real estate industries and exited in 2008. He has held leadership roles at UTC Supply Chain, Numotion, AeroMed, PE-backed companies, and early-stage startups.


  • Our Advisers

    Kenneth Kayser

    Finance & Fintech Adviser


    Kenneth is a tech innovator with 20 years of experience in the finance and fintech industries. He specializes in product development, UX/UI design, commercialization, business development, and investment financing. Kenneth was the co-founder of several tech startups, including Envel Bank, CarScan, and Young Engineers, which are now part of his venture portfolio. He has held leadership roles at Barclays Africa (Absa Group), Nedbank, and Standard Bank.


    Dr. Jean Wang

    Botanical Medicine & Regulatory Adviser


    Dr. Jean Wang has 30 years of experience in natural botanical medicine, pharmaceuticals, life sciences, IT, and data analytics. She led the research & development of medicine and life sciences at Takeda and Bayer, and worked in healthcare & life sciences solution design, data analytics and AI at IBM. She also consulted natural medicine companies & academic institutions on clinical trial strategy for US FDA approval. Dr. Wang holds a PhD in Natural Product Chemistry & Pharmacognosy from the University of Iowa.


    Peter Leighton

    Commercial & Marketing Adviser


    Peter is the founding partner of Abunda, an integrated consulting practice. With 30 years of experience in consumer products, nutrition, functional foods,

    nutraceuticals and biotech, he has led marketing and commercialization strategies for the successful launch of hundreds of products. Peter has served as CEO at Advana Science, VP Marketing & Product Development at Natrol (NTOL), VP at Galileo Laboratories, SVP Marketing at Weider Nutrition (WNI) and Director of Marketing at InterHealth Nutraceuticals.


  • Contact Us

    Send us a message for investment details or more information:


  • Join Us On

    All Posts